A Causal Framework for Quantile Residual Lifetime
剩余寿命分位数的因果分析框架AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要针对处理后存活者选择构造因果目标,并以剩余寿命分位数衡量差异,对应因果推断与分布效应。
剩余寿命分位数的因果分析框架AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
Estimating prognosis conditional on surviving an initial high-risk period is crucial in clinical research. Yet, standard metrics such as hazard ratios are often difficult to interpret, while mean-based summaries are sensitive to outliers and censoring. We propose a formal causal framework for estimating quantiles of residual lifetime among individuals surviving to a landmark time $t_0$. Our primary estimand, the "Observed Survivor Quantile Contrast" (OSQC), targets pragmatic prognostic differences within the observed survivor population. To estimate the OSQC, we develop a doubly robust estimator that combines propensity scores, outcome regression, and inverse probability of censoring weights, ensuring consistency under confounding and informative censoring provided that the censoring model is correctly specified and at least one additional nuisance model is correctly specified. Recognizing that the OSQC conflates causal efficacy and compositional selection, we also introduce a reweighting-based supplementary estimator for the "Principal Survivor Quantile Contrast" (PSQC) to disentangle these mechanisms under stronger assumptions. Extensive simulations demonstrate the robustness of the proposed estimators and clarify the role of post-treatment selection. We illustrate the framework using data from the SUPPORT study to assess the impact of right heart catheterization on residual lifetime among intensive care unit survivors, and from the NSABP B-14 trial to examine post-surgical prognosis under adjuvant tamoxifen therapy across multiple landmark times.